1月5日，长城证券涨1.37%，成交额3.29亿元。两融数据显示，当日长城证券获融资买入额4191.59万 元，融资偿还4934.47万元，融资净买入-742.88万元。截至1月5日，长城证券融资融券余额合计14.51亿 元。 融资方面，长城证券当日融资买入4191.59万元。当前融资余额14.49亿元，占流通市值的3.89%，融资 余额超过近一年60%分位水平，处于较高位。 融券方面，长城证券1月5日融券偿还1.54万股，融券卖出1.88万股，按当日收盘价计算，卖出金额19.44 万元；融券余量13.69万股，融券余额141.55万元，低于近一年10%分位水平，处于低位。 截至12月19日，长城证券股东户数12.68万，较上期减少2.76%；人均流通股28403股，较上期增加 2.84%。2025年1月-9月，长城证券实现营业收入41.21亿元，同比增长44.61%；归母净利润19.31亿元， 同比增长75.83%。 分红方面，长城证券A股上市后累计派现34.36亿元。近三年，累计派现16.98亿元。 机构持仓方面，截止2025年9月30日，长城证券十大流通股东中，香港中央结算有限公司位居第四大流 通股东， ...

1月5日，鹏鼎控股涨2.51%，成交额18.82亿元。两融数据显示，当日鹏鼎控股获融资买入额2.35亿元， 融资偿还2.03亿元，融资净买入3236.80万元。截至1月5日，鹏鼎控股融资融券余额合计13.65亿元。 融资方面，鹏鼎控股当日融资买入2.35亿元。当前融资余额13.57亿元，占流通市值的1.13%，融资余额 超过近一年90%分位水平，处于高位。 分红方面，鹏鼎控股A股上市后累计派现97.25亿元。近三年，累计派现50.97亿元。 机构持仓方面，截止2025年9月30日，鹏鼎控股十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股8239.70万股，相比上期增加3459.08万股。华泰柏瑞沪深300ETF（510300）位居第五大流 通股东，持股1191.88万股，相比上期减少50.88万股。易方达沪深300ETF（510310）位居第七大流通股 东，持股855.80万股，相比上期减少28.22万股。兴全商业模式混合(LOF)A（163415）、兴全合润混合A （163406）、兴全新视野定期开放混合型发起式（001511）退出十大流通股东之列。 责任编辑：小浪快报 融券方面，鹏鼎控股1月 ...

Group 1 - Maduro denies all charges from the U.S. and claims he is still the President of Venezuela [2] - The U.S. has accused Maduro of drug terrorism conspiracy, cocaine smuggling conspiracy, and possession of firearms [2] - Maduro states he was forcibly taken from his home in Caracas [2] Group 2 - China condemns the U.S. for violating Venezuela's sovereignty and international principles [3] - The U.S. is accused of undermining multilateralism and threatening peace in Latin America and the Caribbean [3] Group 3 - Venezuela's oil exports have nearly dropped to zero due to U.S. sanctions and blockade [4] - The Venezuelan oil company is reducing production and closing some oil fields due to accumulated inventory [4] - Shortages of diluents for blending heavy crude oil are further restricting production activities [4] Group 4 - Trump claims the U.S. must have complete access to Venezuela's resources and asserts U.S. control over the country [5][6] - The U.S. Vice President's residence was attacked, with one suspect arrested [6] Group 5 - High expectations for Chinese stocks with projected annual growth of 15% to 20% in 2026 and 2027 [8] - Corporate earnings in China are expected to grow by 14% and 12% in 2026 and 2027, respectively [8] - Factors driving growth include AI applications, international expansion, and policies to reduce internal competition [8]

Group 1 - The core point of the article is that Nantong Chaoda Equipment Co., Ltd. has not yet implemented its previously disclosed share repurchase plan as of December 31, 2025 [1][3] Group 2 - The share repurchase plan was approved by the board on October 27, 2025, with a total funding amount between 25 million yuan and 50 million yuan, and a maximum repurchase price of 65.44 yuan per share [2] - The implementation period for the repurchase plan is within 12 months from the board's approval, ending on October 26, 2026 [2] Group 3 - The company will continue to assess market conditions to implement the repurchase plan within the specified timeframe and will fulfill its information disclosure obligations as required by regulations [4]

Core Viewpoint - Shandong Guocer Functional Materials Co., Ltd. announced the progress of its share repurchase plan, which has not yet been implemented as of December 31, 2025, and will proceed based on market conditions within the designated timeframe [1][3]. Group 1: Repurchase Plan Overview - The company approved a share repurchase plan on November 6, 2025, intending to use its own and raised funds to repurchase shares through centralized bidding, aimed at employee stock ownership plans or equity incentive plans [2]. - The total amount allocated for the repurchase is set between 100 million yuan (inclusive) and 200 million yuan (inclusive), with a maximum repurchase price of 30 yuan per share (inclusive) [2]. - The implementation period for the repurchase is up to 12 months from the board's approval date, concluding by November 5, 2026, and does not require shareholder meeting approval [2]. Group 2: Current Status and Future Plans - As of the end of December 2025, the company has not executed the share repurchase as per the regulations of the Shenzhen Stock Exchange [3]. - The company plans to continue the repurchase according to market conditions and will fulfill its information disclosure obligations as required [4]. - Market analysts view the implementation of the repurchase plan as a recognition of the company's value, which may provide support for the company's stock price [4].

登录新浪财经APP 搜索【信披】查看更多考评等级 无锡洪汇新材料科技股份有限公司（以下简称"无锡洪汇新材"）于2026年1月6日发布回购股份进展公 告，披露了截至2025年12月31日的股份回购实施情况。公告显示，公司已通过集中竞价方式启动股份回 购，资金来源为自有资金，且回购价格未超过此前设定的15.90元/股上限，符合既定回购方案及相关监 管要求。 回购方案回顾：拟斥资1000万至2000万元回购注销股份 据公告披露，无锡洪汇新材于2025年8月15日召开第六届董事会第二次会议，随后在2025年9月5日召开 的2025年第二次临时股东会上，均审议通过了《关于以集中竞价方式回购股份方案的议案》。根据该方 案，公司计划使用自有资金以集中竞价交易方式回购股份，全部用于注销并减少公司注册资本。 具体来看，本次回购的资金总额区间为不低于1000万元（含）且不超过2000万元（含），回购价格上限 为15.90元/股（含）。按此价格上限测算，预计回购股份数量约为62.89万股至125.79万股，约占公司当 前总股本的0.34%至0.69%。回购实施期限为自股东会审议通过之日起不超过6个月，即截至2026年3月5 日。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 浙江金固股份有限公司（下称"金固股份"）于2026年1月5日发布股份回购进展公告，披露截至2025年12 月31日，公司此前披露的3000万元至6000万元股份回购计划尚未实施，主要原因是正在办理开立回购专 用证券账户等事宜。 回购方案回顾：拟斥资3000万至6000万元，用于员工持股或股权激励 据公告回溯，金固股份于2025年12月9日召开第六届董事会第十五次会议，审议通过了《关于回购公司 股份方案的议案》。根据该方案，公司计划使用自有资金及自筹资金，以集中竞价方式回购公司股份， 回购股份拟用于实施员工持股计划或股权激励。 金固股份在公告中表示，后续将根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指 引第9号——回购股份》的相关规定及公司股份回购方案，在回购期限内推进回购事宜，并严格履行信 息披露义务。同时，公司提醒广大投资者注意投资风险。 本次回购计划是金固股份基于对公司未来发展的信心及价值判断，旨在通过回购股份用于员工激励，进 一步完善公司治理结构，调动员工积极性。市场将持续关注公司回购专用证券账户办理进度及后续回购 实施情况。 声明：市场 ...

Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. has announced the progress of its share repurchase plan, indicating that as of December 31, 2025, it has repurchased 2.6932 million shares, accounting for 0.60% of its total share capital, with a total expenditure of 93.8909 million yuan, nearing the lower limit of the repurchase plan of 100 million yuan [1][3]. Group 1: Repurchase Plan Background - The board of directors approved a share repurchase plan on December 15, 2025, intending to use self-owned and/or raised funds to repurchase A-shares through centralized bidding to maintain company value and shareholder rights [2]. - The repurchase plan sets a total fund range of no less than 100 million yuan and no more than 200 million yuan, with a maximum repurchase price of 70 yuan per share, and the implementation period is within three months from the board's approval [2]. Group 2: Repurchase Progress Details - As of December 31, 2025, the company has repurchased 2.6932 million shares through a dedicated securities account via centralized bidding, with the highest transaction price at 37.72 yuan per share, the lowest at 32.15 yuan per share, and an average transaction price of 34.86 yuan per share, totaling 93.8909 million yuan spent (excluding fees) [3]. - The repurchase actions comply with the established plan and relevant legal regulations, adhering to trading time and other restrictions as per the regulations [3]. Group 3: Future Arrangements - The company plans to continue implementing the share repurchase plan based on market conditions within the designated period and will fulfill its information disclosure obligations as required by laws and regulations [4]. - The implementation of this repurchase plan reflects the company's recognition of its value and confidence in future development, aiming to maintain shareholder rights and stabilize market expectations [4].

Core Viewpoint - Zhejiang Jingxing Paper Industry Co., Ltd. has completed its maximum share repurchase plan and extended the repurchase period to February 19, 2026 [1] Group 1: Repurchase Plan and Deadline Adjustment - The company announced a share repurchase plan on November 19, 2024, intending to use self-owned or raised funds to repurchase shares at a price not exceeding 4.00 CNY per share, with a funding scale of 80 million to 150 million CNY [2] - On November 18, 2025, the board approved an extension of the repurchase deadline by three months, changing the end date from November 19, 2025, to February 19, 2026, while other aspects of the plan remained unchanged [2] Group 2: Progress of Repurchase as of December 31 - As of December 31, 2025, the company has repurchased shares through a dedicated securities account via centralized bidding, with the highest transaction price being 4.00 CNY per share, which did not exceed the set price limit [3] Group 3: Compliance and Future Arrangements - The company emphasized that the repurchase process strictly adhered to regulatory requirements, avoiding transactions during sensitive periods and not exceeding daily price limits [4] - The company plans to continue implementing the repurchase plan based on market conditions within the remaining period and will disclose progress in accordance with regulatory requirements [4]

Group 1: Company Overview - Company held a specific investor meeting on January 5, 2026, in Shanghai, attended by nine institutions including Tianfeng Securities and Southern Fund [1][2] - Senior Vice President and Secretary of the Board, Chen Feibiao, along with Securities Affairs Representative Dai Yiyi, discussed key issues such as the progress in the new energy business, overseas base layout, and pharmaceutical business planning [1][2] Group 2: New Energy Business - The new energy business is focused on the sales of LiFSI and electrolyte products, with a breakthrough in revenue achieved in 2025 and expected continued growth in 2026 [2] - The lithium hexafluorophosphate project is currently in the technical improvement stage, with ongoing optimization of product competitiveness through systematic process development [2] - The company leverages its long-standing experience in chemical synthesis to enhance its market position in the new energy sector [2] Group 3: Overseas Operations - The UK production base is operating smoothly in 2026, while the Malaysian base is under phased construction, primarily aimed at producing agricultural CDMO products [3] - The company plans to integrate resources from China, the UK, and Malaysia to provide comprehensive supply chain solutions covering the entire product lifecycle [3] Group 4: Pharmaceutical Business - The pharmaceutical business focuses on a CDMO model and has established partnerships with several leading global pharmaceutical companies, while also expanding its client base [4] - The business primarily serves products under patent, with long-term growth expected as these products are promoted [4] - Future development will emphasize small molecule CDMO, starting materials, and registration materials, while also investing in emerging areas such as peptides and radiopharmaceuticals [4] Group 5: Risk Management - The company acknowledges potential revenue impacts from the expiration of patents for agricultural clients but plans to mitigate this through product and technology upgrades [6]